¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03
±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° (½Ç½Ã°£ È­»ó±³À°)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °­ÇØÁø
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í Àüµî·Ï : ȸ¿ø(±³¼ö,Àü¹®ÀÇ,ÀüÀÓÀÇ) -> 5¸¸¿ø ºñȸ¿ø -> 7¸¸¿ø/ ȸ¿ø(Àü°øÀÇ,°£È£»ç,¾à»ç,±ºÀÇ°ü) -> 3¸¸¿ø, ºñȸ¿ø ->5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ09:00~09:40 Tumor heterogeneity and treatment resistance  Joan S BRUGGE(Harvard Medical School) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ09:40~10:00   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:00~10:22 Adjuvant treatment with IO : one size fits all?? : selection of patients who need adjuvant IO  Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:22~10:44 Conducting clinical trials of adjuvant treatment with targeted therapy  ¹Ú¿¬Èñ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:44~11:06 Incorporation of Palliative Care in ASCO  Ishwaria Mohan Subbiah(The University of Texas MD Anderson Cancer Center) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:06~11:28 Introduction of Korean Academy of Supportive Care in Cancer  ±ÇÁ¤Çý(¼¼Á¾Ãæ³²´ëÇб³º´¿ø) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:28~11:30 Q&A  -(-) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:30~12:10 Tecentriq + Avastin : Reigniting progress in the HCC treatment landscape  À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ12:10~12:40   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ12:40~13:05 Emergence of immunotherapy in HCC: what  Ghassan ABOU-ALFA(MSKCC) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:05~13:30 Dawn of a new era for biliary tract cancer: targeted and immunotherapy  ¿Àµµ¿¬(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:30~13:55 Beyond PARPi and novel therapy in pancreatic cancer  Teresa MACARULLA(VHIO) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:55~14:00 Q&A  -(-) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ14:00~14:20   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ14:20~14:42 Neoadjuvant chemotherapy followed by surgery in locally advanced pancreato-biliary cancer   ÀåÁø¿µ(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ14:42~15:04 Recent advances in neoadjuvant chemotherapy for locally advanced pancreato-biliary cancer  À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:04~15:26 Primary breast surgery for newly diagnosed stage IV breast cancer patients  Á¤¼Ò¿¬(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:26~15:48 How to manage stage IV breast cancer patients with oligometastasis  ±èÇÑÁ¶(¼øõÇâ´ëõ¾Èº´¿ø) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:48~15:50 Q&A  Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ15:50~16:00   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:00~16:20 Bacterial infections and human cancer  Thomas F. MEYER(Max Planck Institute for Infection Biology) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:20~16:40 HBV Infection–Based HCC TME and immunotherapy  Valerie Chew Suk PENG(Translational Immunology Institute (TII)) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:40~17:00 Screening for early nasopharyngeal cancers by circulating Epstein-Barr virus DNA analysis  KC Allen CHAN(The Chinese University of Hong Kong) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ17:00~17:40 Drug development in oncology: the revolution of the last 15 years  Jean-Charles SORIA(Amgen) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2021³â Á¦16Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03
´ÙÀ½±Û ´ëÇÑÇǺΰúÇÐȸ ´ë±¸°æºÏÁöºÎ Á¦ 251Â÷ ÇмúÁý´ãȸ : 2021-09-02
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
330 ÃæºÏ ´ëÇѼҾưúÇÐȸ ÃæºÏ ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á : 2018-09-01 0 600 2018-08-08
329 ÀüºÏ Á¦20ȸ ¿µÈ£³²³»ºÐºñ´ë»çÇÐȸ Çмú´ëȸ : 2018-09-01 0 654 2018-08-08
328 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¿¬¼¼º´¸® ½ÉÆ÷Áö¿ò : 2018-09-01 0 642 2018-08-08
327 ¼­¿ï ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø ½Å°æ¿Ü°ú ½ÉÆ÷Áö¾ö : 2018-08-31 0 894 2018-08-08
326 ¼­¿ï Á¦ 4ȸ ´ëÇÑÇǺÎÁø±ÕÇÐȸ ¿¬¼ö±³À° : 2018-08-31 0 514 2018-08-08
325 ÀüºÏ Á¦20ȸ ¿µÈ£³²³»ºÐºñ´ë»çÇÐȸ Çмú´ëȸ : 2018-08-31 0 1,189 2018-08-08
324 ´ë±¸ ´ë±¸°æºÏ°³¿ø³»°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-08-28 0 1,017 2018-08-08
323 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÒ¸éÁõ ÀÎÁöÇൿġ·á : 2018-08-26 0 1,646 2018-08-08
322 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø Á¦ 23ȸ °¡Å縯 ¾È°ú Çмú ½ÉÆ÷Áö¾ö : 2018-08-26 0 1,625 2018-08-08
321 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ 2018³âµµ Á¦2Â÷ ȸ¿ø¿¬¼ö±³À° : 2018-08-26 0 4,052 2018-08-08
320 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 2ÀÏÂ÷) : 2018-08-26 0 904 2018-08-08
319 ¼­¿ï °í·Á´ëÇб³¾È»êº´¿ø Á¦14ȸ °í·ÁÀÇ´ë ÇǺΰúÇб³½Ç ½ÉÆ÷Áö¾ö ¹× ¿öÅ©¼ó : 2018-08-26 0 708 2018-08-08
318 ´ë±¸ 2018³â Á¦1ȸ ´ëÇÑ°¨¿°ÇÐȸ ¿µ³²Áöȸ ¿¬¼ö°­Á : 2018-08-25 0 879 2018-08-08
317 ´ëÀü 2018 ´ëÇÑ¿Ü°ú¼ú±â¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö ¹× Æ©ÅÍ ¿öÅ©¼ó : 2018-08-25 0 418 2018-08-08
316 Ãæ³² Àü³²´ëÇб³º´¿ø 2018 Á¦ 20Â÷ ºû°íÀ»½½°üÀý¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-08-25 0 725 2018-08-08
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷